Metabolism of MRX-I, a novel antibacterial oxazolidinone, in humans: the oxidative ring opening of 2,3-dihydropyridin-4-one catalyzed by non-P450 enzymes

Time:2015-05-13 / View:620 times

Prev: New potent antibacterial oxazolidinone (MRX-I) with an improved class safety profile

Next: Single- and Multiple-Dose Study to Determine the Safety, Tolerability, Pharmacokinetics, and Food Effect of Oral MRX-I Versus Linezolid in Healthy Adult Subjects

Back